Alnylam Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Good morning, everyone, and thank you for joining us. I'm Salveen Richter, a biotechnology analyst at Goldman Sachs, and we're really pleased to have Alnylam here with us. And with us from Alnylam, we have John Maraganore, CEO of the company.
Questions & Answers
With that, John, to start, can you review your P5x25 vision for 2025? And just comment on how you attain your goal of becoming a top 5 biotech company?
Yes. Well, Salveen, first of all, thanks for having us. Always a pleasure to be at this meeting even when it's virtual. So the P5x25 vision for Alnylam really is part of a decade-long heritage of setting 5-year goals at our company.
We first started with Alnylam 5x15, which we launched in early 2011 and then Alnylam 2020, which we launched in early 2015. And this
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
